News | Drug-Eluting Balloons | November 10, 2021

First-in-man Study Shows Effectiveness of of Biolimus Drug-coated Balloon in Small Coronary Vessels

BIO-RISE CHINA study compares Palin balloon angioplasty to the Biosensors BioRise BA9 coated balloon

Biosensors Rise non-compliant angioplasty balloon

November 10, 2021 — Biosensors International Group Ltd., a developer and manufacturer of innovative medical devices, announced the results of the BIO-RISE CHINA study, sponsored by its sister company, JW Medical Systems Ltd. (Shangdong, China). BIO-RISE CHINA is a multi-center, randomized controlled, superiority trial performed in 10 centers across China under the leadership of Prof. Han Yaling, principal investigator, and co-principal investigators, Dr. Guosheng Fu and Dr Yujie Zhou. This first-in-human study assessed the safety and efficacy of a Biolimus A9 (BA9) coated balloon (DCB) in patients with small vessel coronary artery disease undergoing PCI.

“The excellent results of the BioRise BA9 coated balloon [DCB] in this clinical study mean there is now a new therapeutic option for the treatment of small vessel disease in patients undergoing PCI," Han said.

212 patients were randomized between treatment with the BA9 coated balloon and plain old balloon angioplasty (POBA). The study met its primary end-point by demonstrating a highly statistically significant reduction of late lumen loss with the BA9 coated balloon compared to POBA at nine months (0.16±0.29 mm vs. 0.30±0.35 mm ∆ 0.14 mm; 95% CI -0.23 to -0.05; p = 0.001).

In addition, late lumen enlargement was three times more common with the BA9 coated balloon which was also associated with a trend towards improved clinical outcomes at one year.

This data is the first trial in a series of studies Biosensors and JWMS will conduct worldwide, including the REFORM trial (prospective, randomized, non-inferiority trial to determine the safety and efficacy of the BA9 drug coated balloon for the treatment of in-stent restenosis: first-in-man trial, a head-to-head to study comparing the BioRise DCB with the paclitaxel coated Sequent Please DCB across various centers in Europe.

Related Content

Links to All the TCT 2021 Late-Breaking Clinical Trials

Related Content

Feature | TCT

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 ...

Home November 10, 2021
Home
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Feature | TCT

October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular ...

Home October 15, 2020
Home
News | TCT

October 14, 2020 — The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) are ...

Home October 14, 2020
Home
Videos | TCT

With COVID-19 forcing all medical conferences to go virtual in 2020, Juan F. Granada, M.D., CEO of the Cardiovascular ...

Home August 01, 2020
Home
Feature | TCT | Dave Fornell, Editor

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...

Home November 04, 2019
Home
Feature | TCT

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-breaking ...

Home October 11, 2019
Home
Videos | TCT

Chandan Devireddy, M.D., offers insights about what he saw as the top take aways from the 2019 Transcatheter ...

Home October 04, 2019
Home
Videos | TCT

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo ...

Home October 03, 2018
Home
Feature | TCT

October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clinical ...

Home September 21, 2018
Home
Subscribe Now